Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Preferences for COVID-19 vaccination information and location: Associations with vaccine hesitancy, race and ethnicity

Kimberly A. Fisher a,b,⇑, Ngoc Nguyen b, Sybil Crawford b,c, Hassan Fouayzi b, Sonal Singh b,d, Kathleen M. Mazor a,b

a Department of Medicine, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, United States
b Meyers Health Care Institute, A Joint Endeavor of the UMass Chan Medical School, Reliant Medical Group, and Fallon Health, 385 Grove Street, Worcester, MA 01605, United States
c Tan Chingfen Graduate School of Nursing, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, United States
d Department of Family Medicine and Community Health, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, United States

Article history:
Received 26 March 2021
Received in revised form 7 September 2021
Accepted 22 September 2021
Available online 25 September 2021

Keywords:
COVID-19
COVID-19 vaccines
Vaccine hesitancy
Vaccination

1. Introduction

As the COVID-19 vaccine supply in the United States (US) increases, the plan for vaccinating the vast majority of the population becomes increasingly important. The Biden administration’s national COVID-19 vaccination strategy articulates priorities that include speed, widespread access, a focus on hard-to-reach populations, and equity.[1] It recognizes the need for concerted efforts to overcome COVID-19 vaccine hesitancy[2,3] and disparities in vaccination rates.[4,5] However, there are reasons to be concerned that the current US vaccination strategy may not achieve these priorities due to its reliance on mass vaccination sites and retail pharmacies with limited vaccine availability in physician offices, and lack of widespread primary care physician (PCP) communication with patients about the vaccine.[6,7] The goal of this report is to determine whether patient preferences for how to be informed about the COVID-19 vaccine and where to receive it differ according to vaccination intent and race/ethnicity. Defining and understanding the vaccination preferences of those most at risk for not being vaccinated is essential to ensuring the US COVID-19 vaccination program is optimally structured to overcome vaccine hesitancy and reduce racial disparities in vaccination rates.

2. Methods

2.1. Participants and survey administration

We conducted a cross sectional survey using Prolific Academic Ltd, an online platform for research participant recruitment, with more than 80,000 active US panel members, from all US states. [8] Eligibility criteria included age ≥ 18 years, English-speaking, and US residency. We restricted the sample to panel members who identified as White, Black or Latino, with oversampling of Blacks and Latinos compared to their representation in the general US population, based on existing evidence of higher levels of vaccine hesitancy in these groups.[2,3] The electronic survey was released between January 12 – February 1, 2021, until the target sample (n ~ 1800) was reached. Participants received ~$1.50 consistent with Prolific recommendations. This study was reviewed by the UMass Chan Medical School Institutional Review Board and deemed exempt.
2.2. Measures

The dependent variables, participants’ preferences for being informed about a COVID-19 vaccine and vaccination location, were assessed with two questions: (1) If your doctor’s office wanted to inform you about a COVID-19 vaccine, how would you want them to do so? Response options included email; online portal message; telephone call; text message; mailed letter; conversation with my doctor when I come for an appointment; no preference; and (2) Where would you prefer to go to get the COVID-19 vaccine? Response options included: doctor’s office; pharmacy; other; no preference.

Primary predictors included vaccination intent and self-identified race/ethnicity. Vaccination intent was assessed by the question: If you could get vaccinated for COVID-19 today, would you? Please assume enough vaccine for everyone. Response options included: Yes; No; Not sure; I have already been vaccinated. We defined vaccine hesitancy as responding “No” or “Not sure” to this question. Self-identified race/ethnicity was categorized as Latino, Black, and White. Additional demographic items included age, sex, and self-rated overall health. Survey items are shown in Supplemental Table 1.

2.3. Analyses

Participants who were already vaccinated were excluded from these analyses. Participant characteristics were summarized using frequencies and percentages. We used crosstabulations and chi-square testing to estimate unadjusted associations of vaccination preferences with vaccination intent and race/ethnicity. We also stratified associations of vaccination preferences with vaccination intent by race/ethnicity. We calculated separate chi-square tests and associated P-values comparing “not sure” to “yes” and “no” to “yes”.

We estimated adjusted associations between dependent variables and primary predictors using multinomial logistic regression, modeling “not sure” vs “yes” and “no” vs “yes”. Gender, US census region, and self-rated overall health were not associated with preferences and so were not included in the models. Vaccination intent, race, and age were added in stepwise forward manner. To assess whether associations between vaccination intent and preferences varied by race/ethnicity, we tested for interactions between vaccination intent and race/ethnicity.

3. Results

There were 1706 responses to this survey, after removing those who failed the attention check (n = 93) and those who did not respond to the vaccination intent question (n = 10). After excluding 38 (2.3%) already-vaccinated participants, 1,668 were included in these analyses. Of these, 887 (53.2%) identify as female, 580 (34.8%) as White, 555 (33.3%) as Black, and 530 (31.8%) as Latino. The mean age of participants was 34.4 years (range 18–76). Participants were geographically diverse across US census regions with 755 (45.3%) from the South, 345 (20.7%) from the West, 284 (17.1%) from the Midwest and 281 (16.9%) from the Northeast. There was at least one participant from all US states except Alaska. At the time of the survey, almost half of the participants (n = 756; 45.3%) were vaccine hesitant with 341 (20.4%) responding “not sure” and 415 (24.9%) responding “no” when asked if they would get vaccinated for COVID-19.

Participants’ preferences for how to be informed about a COVID-19 vaccine differed by vaccination intent and race (Table 1). Participants who answered “not sure” or “no” to vaccination intent were significantly more likely to prefer a conversation with their doctor compared to those who answered “yes” (25.0% vs 7.8%, P < .001 and 23.4% vs 7.8%, P < .001, respectively). Preferences for how to be informed differed by race/ethnicity (P = .001). For example, Black participants were more likely to prefer a conversation with their doctor (20.0%), compared to Latino (14.0%) or White (11.7%) participants. Adjusting for vaccination intent and age attenuated this association (data not shown).

Nearly half of the participants (47.1%) did not have a preference for a vaccination location (Table 2). However, among participants who are not sure whether they will be vaccinated, almost two-thirds (61.8%) prefer to be vaccinated at a doctor’s office, compared with 35.2% of those who intend to be vaccinated (P < .001). Preferred location differed by race/ethnicity (P < .001) with 67.6% of Black “not sure” participants preferring to be vaccinated at a doctor’s office compared to 60.2% of Latino and 54.9% of White “not sure” participants. Adjusted differences in vaccination location preferences by intent and race were similar to unadjusted differences.

We did not detect race/ethnicity effect modification of associations of vaccine hesitancy with dependent variables.

4. Discussion

We describe significant differences in preferences for how to be informed about a COVID-19 vaccine and where to be vaccinated based on vaccine hesitancy and race. Our findings that vaccine hesitancy and Black race are associated with preferring to be informed about the COVID-19 vaccine via a conversation with one’s doctor and to be vaccinated at a doctor’s office underscore the need for healthcare providers to be integrated into COVID-19 vaccination programs, which has not been the case in the US to date. These findings are consistent with other studies that have shown that healthcare providers are the most trusted source of information regarding the COVID-19 vaccine and that an overwhelming majority of individuals say they will turn to healthcare providers when deciding whether to be vaccinated, across all demographic groups.[2] It is well established that a healthcare provider recommendation increases the uptake of influenza and human papillomavirus vaccines,[9,10] which suggests that incorporating preferences for healthcare provider involvement into vaccination strategies is likely to translate into increased vaccine uptake. Our study adds to an accumulating body of evidence indicating that healthcare providers play an essential role in promoting vaccine uptake, including for COVID-19.

Our findings suggest that the US vaccination program, in which PCPs are not currently at the center, needs to be adjusted to leverage the potential of healthcare providers to influence COVID-19 vaccine uptake among hesitant and minority individuals. As the COVID-19 vaccine is now widely available, a shift in delivery from mass vaccination sites and retail pharmacies to doctor’s offices may be an important means of overcoming vaccine hesitancy and achieving equity. Our findings highlight the need to consider structural factors, such as how information is disseminated and where vaccinations are offered, that may influence whether vaccine hesitant individuals choose to be vaccinated.

The study has limitations, including the use of an online research panel and inclusion of English-speaking participants only which may limit generalizability and precludes response rate reporting. We did not include mass vaccination sites as a response option as these had not emerged as a predominant vaccination location at the time of survey administration. There are multiple possible reasons that someone who is hesitant to be vaccinated may prefer to be vaccinated at a doctor’s office. Our study is not designed to elucidate the specific reasons individuals who are hesitant to be vaccinated prefer to be vaccinated at a doctor’s offices and it does not suggest specific communication strategies for providers to address
vaccine hesitancy. While these are important topics for further study, our finding of an association between COVID-19 vaccine hesitancy and preference to be vaccinated at a doctor’s office and to be informed about the COVID-19 vaccine through a conversation with one’s doctor nonetheless indicates that making the COVID-19 vaccine widely available at doctor’s offices is likely to be an important factor in overcoming vaccine hesitancy even as efforts to better understand reasons for vaccine hesitancy are ongoing. The strength of this study is the identification of timely and actionable preferences of vaccine hesitant individuals and racial minorities.

Table 1
Participant Responses to The Question, “If Your Doctor’s Office Wanted to Inform You about a COVID-19 Vaccine, How Would You Want Them to Do So?”, by Vaccination Intent and Race.

| Overall (n = 1668) | Yes (n = 912) | Vaccine Hesitant Participants | P Value (Not Sure vs Yes / No vs Yes) |
|-------------------|--------------|------------------|-------------------------------------|
|                    | Not Sure (n = 341) | No (n = 415)       |                                     |
| **All participants** |                           |                  |                                     |
| Email              | 515 (30.9)     | 321 (35.2)       | 87 (25.6)                            | 107 (25.9)                            | <0.001/<0.001 |
| Conversation with my doctor | 253 (15.2)     | 71 (7.8)         | 85 (25.0)                            | 97 (23.4)                             |                                     |
| Text message       | 252 (15.1)     | 176 (19.3)       | 38 (11.2)                            | 38 (9.2)                              |                                     |
| Telephone call     | 190 (11.4)     | 132 (14.5)       | 37 (10.9)                            | 21 (5.1)                              |                                     |
| Mailed letter      | 86 (5.2)       | 36 (4.0)         | 24 (7.1)                             | 26 (6.3)                              |                                     |
| Online portal message | 83 (5.0)       | 39 (4.3)         | 20 (5.9)                             | 24 (5.8)                              |                                     |
| No preference      | 287 (17.2)     | 137 (15.0)       | 49 (14.4)                            | 101 (24.4)                            |                                     |
| **Latino participants** | N = 530        | N = 353          | N = 92                               | N = 85                                |                                     |
| Email              | 176 (33.3)     | 128 (36.3)       | 27 (29.4)                            | 21 (25.0)                             | 0.001/<0.001 |
| Conversation with my doctor | 74 (14.0)      | 34 (9.6)         | 22 (23.9)                            | 18 (21.4)                             |                                     |
| Text message       | 89 (16.8)      | 72 (20.4)        | 9 (9.8)                              | 8 (9.5)                               |                                     |
| Mailed letter      | 49 (9.3)       | 34 (9.6)         | 11 (12.0)                            | 4 (4.8)                               |                                     |
| Online portal message | 19 (3.6)       | 11 (3.1)         | 4 (4.4)                              | 4 (4.8)                               |                                     |
| No preference      | 91 (17.2)      | 57 (16.2)        | 10 (10.9)                            | 24 (28.6)                             |                                     |
| **Black participants** | N = 555        | N = 226          | N = 145                              | N = 184                               |                                     |
| Email              | 162 (29.2)     | 81 (35.8)        | 34 (23.6)                            | 47 (25.5)                             | <0.001/<0.001 |
| Conversation with my doctor | 111 (20.0)     | 19 (8.4)         | 41 (28.5)                            | 51 (27.7)                             |                                     |
| Text message       | 61 (11.0)      | 32 (14.2)        | 17 (11.8)                            | 12 (6.5)                              |                                     |
| Telephone call     | 73 (13.2)      | 49 (21.7)        | 15 (10.4)                            | 9 (4.9)                               |                                     |
| Mailed letter      | 25 (4.5)       | 7 (3.1)          | 7 (4.9)                              | 11 (6.0)                              |                                     |
| Online portal message | 30 (5.4)       | 11 (4.9)         | 9 (6.3)                              | 10 (5.4)                              |                                     |
| No preference      | 92 (16.6)      | 27 (12.0)        | 21 (14.6)                            | 44 (23.9)                             |                                     |
| **White participants** | N = 580        | N = 331          | N = 104                              | N = 145                               |                                     |
| Email              | 176 (30.3)     | 111 (33.5)       | 26 (25.0)                            | 39 (26.9)                             | <0.001/<0.001 |
| Conversation with my doctor | 68 (11.7)      | 18 (5.4)         | 22 (21.2)                            | 28 (19.3)                             |                                     |
| Text message       | 102 (17.6)     | 72 (21.8)        | 12 (11.5)                            | 18 (12.4)                             |                                     |
| Telephone call     | 67 (11.6)      | 48 (14.5)        | 11 (10.6)                            | 8 (5.5)                               |                                     |
| Mailed letter      | 25 (5.0)       | 12 (3.6)         | 8 (7.7)                              | 9 (6.2)                               |                                     |
| Online portal message | 34 (5.9)       | 17 (5.1)         | 7 (6.7)                              | 10 (6.9)                              |                                     |
| No preference      | 104 (17.9)     | 53 (16.0)        | 18 (17.3)                            | 33 (22.8)                             |                                     |

* Participants who responded ‘other’ (n = 34) were excluded because the open-ended responses in this category differed by vaccination intent. There are n = 6 missing responses to the dependent variable. There are n = 3 missing values for race/ethnicity.

Table 2
Participant Responses to the Question “Where Would You Prefer to Go to Get the COVID-19 Vaccine?” by Vaccination Intent and Race.

| Overall (n = 1634) | Yes (n = 902) | Vaccine Hesitant Participants | P Value (Not Sure vs Yes / No vs Yes) |
|-------------------|--------------|------------------|-------------------------------------|
|                    | Not Sure (n = 335) | No (n = 397)       |                                     |
| **All participants** |                           |                  |                                     |
| Doctor’s office    | 683 (42.0)    | 317 (35.2)       | 205 (61.8)                          | 161 (40.7)                            | <0.001/<0.001 |
| Pharmacy           | 178 (10.9)    | 129 (14.3)       | 23 (6.9)                            | 26 (6.6)                              |                                     |
| No preference      | 767 (47.1)    | 454 (50.4)       | 104 (31.3)                          | 209 (32.8)                            |                                     |
| **Latino participants** | N = 523        | N = 351          | N = 89                              | N = 83                                |                                     |
| Doctor’s office    | 204 (39.2)    | 119 (34.0)       | 53 (60.2)                           | 32 (38.6)                             | <0.001/0.31 |
| Pharmacy           | 66 (12.7)     | 51 (14.6)        | 8 (9.1)                             | 7 (8.4)                               |                                     |
| No preference      | 251 (48.2)    | 180 (51.4)       | 27 (30.7)                           | 44 (33.0)                             |                                     |
| **Black participants** | N = 550        | N = 226          | N = 144                              | N = 180                               |                                     |
| Doctor’s office    | 283 (51.7)    | 103 (45.8)       | 96 (67.6)                           | 84 (46.7)                             | <0.001/0.02 |
| Pharmacy           | 44 (8.0)      | 27 (12.0)        | 9 (6.3)                             | 8 (4.4)                               |                                     |
| No preference      | 220 (40.2)    | 95 (42.2)        | 37 (26.1)                           | 88 (48.9)                             |                                     |
| **White participants** | N = 558        | N = 321          | N = 102                             | N = 133                               |                                     |
| Doctor’s office    | 194 (34.8)    | 93 (18.8)        | 56 (54.9)                           | 45 (34.1)                             | <0.001/0.09 |
| Pharmacy           | 68 (12.2)     | 51 (15.8)        | 6 (5.9)                             | 11 (8.3)                              |                                     |
| No preference      | 295 (53.0)    | 179 (55.4)       | 40 (39.2)                           | 76 (37.6)                             |                                     |

* There are n = 2 missing responses to the dependent variable. There are n = 3 missing values for race/ethnicity.
that can be used to modify vaccination programs to increase the likelihood of reaching hesitant individuals and achieving equity.

5. Conclusions

Incorporating healthcare providers in the COVID-19 vaccination process in the US may increase vaccination among vaccine hesitant individuals and racial minorities.

Funding

This project has been funded in whole or in part with federal funds from the National Library of Medicine, National Institutes of Health, under Cooperative Agreement UG4LM012347 with the University of Massachusetts, Worcester.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2021.09.058.

References

[1] The White House. National strategy for the COVID-19 response and pandemic preparedness. https://www.whitehouse.gov/wp-content/uploads/2021/01/National-Strategy-for-the-COVID-19-Response-and-Pandemic-Preparedness.pdf; 2021 [accessed 10 March 2021].
[2] Hamel L, Kirzinger A, Lopes I, Kearney A, Sparks G, Brodie M. KFF COVID-19 vaccine monitor: January 2021. Kaiser Family Foundation, https://www.kff.org/report-section/kff-covid-19-vaccine-monitor-january-2021-vaccine-hesitancy/; 2021 [accessed 4 March 2021].
[3] Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes toward a potential SARS-CoV-2 vaccine: A survey of U.S. adults. Ann Intern Med 2020;173(12):964–73.
[4] Ndugga N, Pham O, Hill L, Artiga S. Early state vaccination data raise warning flags for racial equity. Kaiser Family Foundation, https://www.kff.org/policy-watch/early-state-vaccination-data-raise-warning-flags-racial-equity/; 2021 [accessed 4 February 2021].
[5] Recht H, Weber L. Black Americans are getting vaccinated at lower rates than White Americans. Kaiser Health News, https://khn.org/news/article/black-americans-are-getting-vaccinated-at-lower-rates-than-white-americans/; 2021 [accessed 17 January 2021].
[6] Goodnough A. In quest for herd immunity, giant vaccination sites proliferate. The New York Times, https://www.nytimes.com/2021/02/28/health/covid-vaccine-sites.html; 2021 [accessed 9 March 2021].
[7] Jean-Jacques M, Bauchner H. Vaccine distribution—equity left behind? JAMA 2021;325(9):829–30.
[8] Prolific. https://www.prolific.co [access 9 March 2021].
[9] Lu P-J, Srivastav A, Amaya A, Dever JA, Roycroft J, Kuritz MS, et al. Association of provider recommendation and offer and influenza vaccination among adults aged ≥18 years - United States. Vaccine 2018;36(6):890–8.
[10] Smith PJ, Stokley S, Bednarczyk RA, Orenstein WA, Omer SB. HPV vaccination coverage of teen girls: the influence of health care providers. Vaccine 2016;34(13):1604-1610. Back to top